**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 39217**

**Manuscript Type:** **ORIGINAL ARTICLE**

***Basic Study***

**Moxibustion treatment modulates the gut** **microbiota and immune function in a dextran sulphate sodium -induced colitis rat model**

Qi Q *et al*. Moxibustion modulates gut microbiota in colitis

Qin Qi, Ya-Nan Liu, Xiao-Ming Jin, Lin-Shuang Zhang, Cun Wang, Chun-Hui Bao, Hui-Rong Liu, Huan-Gan Wu, Xiao-Mei Wang

**Qin Qi, Ya-Nan Liu,** **Cun Wang,** Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China

**Xiao-Ming Jin**, Stark Neurosciences Research Institute and Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, United States

**Lin-Shuang Zhang**, Zhejiang Institute for Food and Drug Control, Hangzhou 310052, Zhejiang Province, China

**Chun-Hui Bao, Hui-Rong Liu, Huan-Gan Wu, Xiao-Mei Wang,** Shanghai Research Institute of Acupuncture-moxibustion and Meridian, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China

**ORCID number:** Qin Qi (0000-0002-0563-1560); Ya-Nan Liu (0000-0002-3290-9206); Xiao-Ming Jin (0000-0002-8671-8640); Lin-Shuang Zhang (0000-0003-4043-8528); Cun Wang (0000-0003-4441-817X); Chun-Hui Bao (0000-0002-9763-0046); Hui-Rong Liu (0000-0002-9697-5085); Huan-Gan Wu (0000-0003-1725-6881); Xiao-Mei Wang (0000-0003-1962-0827).

**Author contributions:** Wang XM conceived and designed the study; Wang XM and Qi Q wrote the main manuscript text; Liu YN and Qi Q performed animal experiments; Jin XM collected data; Wang C and Bao CH analyzed data; Liu HR and Wu HG prepared figures and tables; Jin XM and Zhang LS edited and improved the manuscript; all authors reviewed the manuscript.

**Supported by** theNational Natural Science Foundation of China, No. 81473758; and National Basic Research Programme of China (973 Programme), No. 2015CB554500.

**Institutional review board statement:** The study was reviewed and approved by the Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine (IACUC protocol number: 201611006).

**Conflict-of-interest statement:** To the best of our knowledge, no conflict of interest exists.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Xiao-Mei Wang, MD, PhD, Associate Professor,** Shanghai Research Institute of Acupuncture-moxibustion and Meridian, Shanghai University of Traditional Chinese Medicine, 650 South Wanping Road, Xuhui District, Shanghai 200030, China. wxm123@vip.sina.com

**Telephone:** +86-21-64381106

**Received:** April 9, 2018

**Peer-review started:** April 9, 2018

**First decision:** May 9, 2018

**Revised:** May 22, 2018

**Accepted:** June 25, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate the effect and mechanism of moxibustion in rats with ulcerative colitis.

***METHODS***

A rat colitis model was established by administering 4% dextran sulphate sodium solution. Seventy male rats were randomly divided into seven groups: healthy controls (HC), ulcerative colitis model group (UC), UC with 7 d of moxibustion (UC-7), UC with 14 d of moxibustion (UC-14), UC with mesalazine gavage, HC with 7 d of moxibustion, HC with 14 d of moxibustion. Moxibustion was applied to the bilateral Tianshu (ST25). Gut microbiome profiling was conducted by 16S rRNA amplicon sequencing, and the expression of inflammatory cytokines in colon mucosa and serum was determined by PCR and ELISA, respectively.

***RESULTS***

Moxibustion treatment restored the colonic mucosa and decreased submucosal inflammatory cell infiltration in colitis rats. Rats treated with moxibustion and mesalazine had significantly lower levels of the dominant phyla *Proteobacteria* and the genera *Saccharibacteria*, *Sphingomonas* and *Barnesiella* than colitis rats, they could restore the microbiome to levels similar to those observed in healthy rats. UC rats had reduced alpha diversity, which could be alleviated by moxibustion therapy, and UC-7 had a higher alpha diversity than UC-14. This finding suggests that short-term (7 d) but no longer term (14 d) moxibustion treatment may significantly affect the gut microbiome. The potential bacterial functions affected by moxibustion may be ascorbate and aldarate and amino acid metabolism. Compared with HC group, the levels of the cytokines interleukin-12 (IL-12) (*P* < 0.05) and IL-6, IL-17, IL-23, interferon-γ, lipopolysaccharide, IgA, tumour necrosis factor-α and its receptors 1 (TNFR1) and TNFR2 (*P* < 0.01) were all increased, whereas anti-inflammatory cytokine IL-2 and IL-10 (*P* < 0.01) and transforming growth factor-β (*P* < 0.05 ) were decreased in UC rats, all these changes could be reversed by moxibustion.

***CONCLUSION***

Our findings suggest that moxibustion exerts its therapeutic effect by repairing mucosal tissue damage and modulating the gut microbiome and intestinal mucosal immunity.

**Key words:** Ulcerative colitis; Moxibustion; 16S rRNA; Gut microbiome; Inflammatory cytokine

© **The Author(s) 2018**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tips:** Ulcerative colitis (UC) is a form of inflammatory bowel disease and microbial dysbiosis is an important pathological factor of UC. Moxibustion treatment can repair mucosal tissue damage and regulate immune function in patients with UC associated with gut microbiome changes. In this study, moxibustion can significantly reduce the colonic tissue damage and the levels of pro-inflammatory cytokines and anti-inflammatory cytokines in rats with 4% dextran sulphate sodium-induced ulcerative colitis, relieve intestinal inflammation, and promote the restoration of impaired colonic tissue. In addition, moxibustion can increase the diversity of gut microbiome and the UC with 7 d of moxibustion had a higher alpha diversity than UC with 14 d of moxibustion.

Qi Q, Liu YN, Jin XM, Zhang LS, Wang C, Bao CH, Liu HR, Wu HG, Wang XM. Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium -induced colitis rat model. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

The gut microbiome has been referred to as a ‘forgotten organ’[1] due to its capacity to influence host physiology. The gut microbiome is incredibly diverse, with dominant phyla including *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, *Verrucomicrobia*, *Actinobacteria* and *Fusobacteria*[2,3]. Gut microbiome composition varies substantially among individuals and is thought to be a key determinant of susceptibility to several diseases[4-6]. The gut microbiome provides signals that promote immune cell maturation and ensure the normal development of immune function[7], which is crucial for human life and profoundly influences human physiology and metabolism[8,9].

Ulcerative colitis (UC) is a form of inflammatory bowel disease that can lead to bloody diarrhoea, passage of pus and/or mucus, and abdominal cramping during bowel movements[10,11]. Immune dysfunction plays a key role in driving inflammatory responses during UC development and progression. UC is commonly treated with therapeutics such as the anti-inflammatory drugs mesalazine and sulphasalazine, with steroid enemas[12] or with surgical intervention. The aetiology and pathogenesis of UC have not been fully elucidated but are thought to result from detrimental interactions among intestinal microbiota, the gut epithelium, and the host immune system in genetically susceptible individuals[13,14]. Several studies have recently reported decreased gut microbial diversity in patients with active UC[15,16]. Microbial dysbiosis is an important pathological factor of UC that affects host mucosal immunity[17-19]. Pathogenic bacteria and opportunistic pathogens interact with the intestinal mucosa directly or indirectly via secreted toxins, which may lead to an inappropriate intestinal mucosal immune response.

Studies have demonstrated that moxibustion, a traditional Chinese therapy that treats and prevents diseases using moxa (floss of *Arte**misia argyi*), is a safe and effective treatment for UC[20-23]. Moxibustion exerts its therapeutic effects by regulating immune function[24,25], apoptosis[26,27], and protein expression at acupuncture points and in colon tissues[28,29]. UC is associated with changes in the gut microbiome, and moxibustion modulates the imbalance of intestinal flora[30]. Nevertheless, the gut microbiome is a complex community with only a small proportion of culturable organisms, and the effect of moxibustion on the gut microbiome remains unknown. Recently developed culture-independent high-throughput sequencing methods allow gut microbiome profiling and assessments of microbial gene abundance and community structure to be performed more easily[31].

Here, we used 16S rRNA gene sequencing to assess the gut microbial composition and community structure in faecal samples of UC rats treated with moxibustion or mesalazine gavage. Our aims were to determine the impact of moxibustion on intestinal microbial community structure, the role of the intestinal microbiota in UC pathogenesis, and the molecular mechanism underlying the effect of moxibustion in UC treatment.

**MATERIALS AND METHODS**

***Rats and groups***

Seventy specific pathogen-free male Sprague Dawley rats (body weight 180-220 g) were provided by the Department of Laboratory Animal Science of Fudan University (Shanghai Slack Laboratory Animal Co., LTD. license: SCXK (Shanghai) 2012-0002 and SYXK (Shanghai) 2009-0082). All rats were raised under standard conditions: 25 ± 1°C; 50%–70% humidity; 12 h light/dark cycle. Rats were allowed to acclimatize for one week before the start of the trial. Rats (*n* = 70) were divided into seven groups: healthy controls (HC), healthy controls with 7 d of moxibustion (HC-7), healthy controls with 14 d of moxibustion (HC-14), UC model group (UC), UC model with 7 d of moxibustion (UC-7), UC model with 14 d of moxibustion (UC-14), and UC model with mesalazine gavage (UC-W). UC was induced with 4% dextran sulphate sodium (DSS; molecular weight: 36000-50000 Da; Art.No.9011-18-1; MP Biomedicals) supplied in drinking water. Animal breeding, care and all experiments were performed according to procedures approved by the University Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine (IACUC protocol number :SYXK (shanghai) 2009-0082) to relieve pain and avoid injury. All protocols were performed in strict accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals, as formulated by the Ministry of Science and Technology of the People’s Republic of China[32]. We tried all efforts to minimize animal suffering.

***DSS-induced-colitis***

UC was induced with 4% DSS in drinking water for 7 consecutive days as described previously[33]. After 7 d, two rats were randomly selected to confirm successful establishment of the animal model. Rats were provided 1% DSS in the drinking water for 7 consecutive days in the UC, UC-7 and UC-W groups and 14 consecutive days in the UC-14 group.

***Treatment***

For the HC-7 (*n* = 10) and UC-7 (*n* = 10) groups, moxa cones (0.5 cm in diameter and 0.6 cm high) (Nanyang Hanyi Moxa Co., Ltd. China) were placed on Tianshu (ST25, bilateral) with moxibustion for 10 min once a day for 7 d, and the skin temperature of acupuncture points was 43 ± 1°C. ST25 is 5 mm lateral to anterior midline at the navel level[34]. The HC-14 (*n* = 10) and UC-14 (*n* = 10) groups received the same treatment as the HC-7 and UC-7 groups, respectively, but for 14 instead of 7 d. The UC-W group (*n* = 10) received mesalazine enteric-coated tablets (Heilongjiang Tianhong Pharmaceutical Co., Ltd; Lot number: H20103359) by gavage administration twice daily for 7 consecutive days with a dose calculated from that specified for an adult of 70 kg and a weight ratio of 1:0.018 for rats (200 g). The HC (*n* = 10) and UC (*n* = 10) groups did not receive any treatment but received the same fixation (to fix the hands and feet on the fixed mount).

***Sample collection and processing***

Following treatment, rats were anaesthetized via intraperitoneal injection with 2% pentobarbital sodium for tissue collection. Blood samples were collected by abdominal aortic, after 1 h’s standing, the samples were centrifuged at 3000 rpm for 10 min at 4°C to separate the plasma. The obtained plasma was stored at −80°C. Colon samples were rapidly removed and separated from the large intestine (6 cm distal to the anus). Then, 5 g of faecal matter was collected in cryogenic vials and stored at −80°C. Colon samples were flushed with physiological saline to remove the surrounding connective tissue and fat. Colonic mucosal injury was observed with the naked eye. Then, the colon was divided into two segments: one segment was fixed in 10% paraformaldehyde for haematoxylin and eosin (HE) staining for histological observation and the histological grade was scored with the bland method[30] (Table 1), whereas the other segment was stored at −80°C.

***Haematoxylin and eosin staining***

Colon samples fixed with 10% paraformaldehyde were dehydrated and immersed in wax using an automatic tissue dehydrating machine, embedded in paraffin and sectioned at 4-µm thickness with a microtome. Slices were incubated with xylene I and II for 20 min each and rehydrated in absolute alcohol, 95% alcohol, 85% alcohol and 75% alcohol (3 min each time). Slices were stained with haematoxylin for 1 min, followed by 1% hydrochloric acid-alcohol for 30 s, and counterstained with eosin for 5 min. Sample histology was observed by electron microscope.

***Bacterial genomic DNA extraction***

Genomic DNA was extracted from faecal samples using the QIAamp DNA Mini Kit (QIAGEN, Germany). Briefly, 20 μL of proteinase K solution (20 mg/mL) and 100 mg of zirconium beads (0.1 mm) were added to the pellet. The mixture was agitated three times with a Mini-Beadbeater (FastPrep, Thermo Electron Corporation, USA); buffer AL was added to the mixture, which was then incubated for 10 min at 70°C. Next, 200 μL of ethanol (96%) was added. This mixture was then loaded onto a QIAamp Mini spin column and centrifuged at 8000 *g* for 1 min. The column material was washed with the first washing buffer (buffer AW1, 500 μL) followed by the second washing buffer (buffer AW2, 500 μL) provided with the kit. Finally, DNA was eluted with 100 μL of buffer AE. DNA integrity was assessed by electrophoresis on a 1% agarose gel containing 0.5 mg/mL ethidium bromide. DNA concentrations were determined using a NanoDrop ND-2000 spectrophotometer (Thermo Electron Corporation).

***Illumina sequencing and data processing***

The 16S rRNA gene hypervariable V3-V4 region was amplified by PCR using the barcode-tag universal bacterial modified primers. The prototype primers were 341F (5’ -ACTCCTACGGGAGGCAGCAG- 3’) and 806R (5’ -GGACTACVVGGGTATCTAATC- 3’). Amplicon sequencing was performed using Illumina MiSeq (PE300). Raw reads were demultiplexed and filtered according to read length and quality. Chimeric reads were removed, and OTU selection was performed as previously described[35]. The filtered reads were dereplicated to unique sequences and sorted by abundance before being subjected to OTU clustering at 97% similarity. Taxonomy was assigned to the representative sequence of each OTU using the Ribosomal Database Project classifier[36].

***Prediction of metagenome functional content***

Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt 1.0.0)[37] was used to predict metagenome function from the 16S rRNA data. Statistical Analysis of Metagenomic Profiles (STAMP)[38] was used to analyse the predicted metagenome and to identify pathways associated with UC. The Benjamini-Hochberg procedure was used to control the false discovery rate due to multiple testing.

***PCR analysis***

Total RNA was isolated using TRIzol® LS (Invitrogen Corp.) according to the manufacturer’s instructions. The integrity of the RNA samples was assessed via agarose gel (10 g/L) electrophoresis, and RNA concentrations were determined using a NanoDrop ND-2000 Spectrophotometer (Thermo Electron Corporation). Two micrograms of total RNA was used for RT-PCR in a 20-µL reverse transcription reaction system. Two micrograms of RNA, up to 8 µL of DEPC, 0.5 µL (50 U/µL) of RNase inhibitor and 2 µL of oligomer (dT)15 and primer were mixed and placed in 65°C water for 5 min. Then, the mixture was placed at room temperature for 10 min. After a 5-s centrifugation, the following reagents were added to the reactions: 0.5 µL (50 U/µL) of RNase inhibitor, 4 µL of 5× RT buffer solution, 2 µL of dNTPs (10 mmol/L for each), 2 µL of DTT, and 1 µL of AMV reverse transcriptase (200 U/µL). The solution was mixed and placed in water at 40°C for 1 hour, heated to 90°C in water for 5 min, and centrifuged for 5 s.

The primers used were designed with Primer Express Software v2.0 (Applied Biosystems, USA) and synthesized at the Beijing Genomics Institute. Gene sequences of the primers are presented in Table 2.

Each total 16-µL PCR included: 8 µL of 2×SYBR Green PCR mix, 1 µL of each sense and antisense primers, 1 µL of reverse transcription product (cDNA), and 5 µL of H2O. RT-PCR was performed using a ViiA 7 Real Time PCR System (Applied Biosystems, USA). The reaction conditions were set at 95°C for 2 min, 94°C for 10 s, 60°C for 10 s, and 72°C for 40 s for 40 cycles.

***ELISA analysis***

The levels of interleukin-2, 10, 12, 17, 23, interferon-γ(IFN-γ), lipopolysaccharide (LPS), immunoglobulin A (IgA), transforming growth factor-β (TGF-β), tumour necrosis factor-α (TNF-α), TNF receptor 1 (TNFR1) and TNFR2 in all serum samples were tested by sandwich ELISA. According to manufacturer's instructions, IL-2, IL-10, IL-12, 17, IL-23, IFN-γ, LPS, IgA, TGF-β, TNF-α, TNFR1 and TNFR2 were measured using corresponding ELISA kits (Biotech well, shanghai, china). The detection limits were: 17pg/mL for IL-2, IL-12, IL-23, TNF-α, 16 pg/mL for IL-10, 15 pg/mL for IL-17, TGF-β, 12 pg/mL for IFN-γ, 8 pg/mL for LPS, 8ng/mL for IgA, 6 pg/mL for TNFR1, 5 pg/mL for TNFR2.

***Statistical analysis***

Differential abundance testing between groups was performed using the Kruskal-Wallis test in R 3.2.3 (http://cran.r-project.org). Alpha diversity was measured with Simpson and Shannon diversity indices. Beta diversity was determined using unweighted unifrac distance and was summarized by PCoA. A principal components analysis (PCA) plot of Kyoto Encyclopaedia of Genes and Genomes (KEGG) modules with significant differences in mean proportion differences was created using STAMP[39] (v2.1.3). Body weight gain, RT-PCR and ELISA analysis data are presented as the means ±SDs. Histopathological score data are expressed as M (Q25-Q75). ANOVA and Least Significant Difference multiple comparison tests were performed using IBM SPSS statistics 21.0 (IBM Co., Armonk, NY, USA). *P*< 0.05 was considered significant.

**RESULTS**

***Body weight gains in different groups***

Two rats in the UC-W group died after gavage during the experiment. The body weight gain in the UC group was lower than that in the HC group (*P* < 0.01). After treatment, the body weight gains in the UC-7, UC-14, HC-7, HC-14 (*P* < 0.01) and UC-W (*P* < 0.05) groups were higher than that in the UC group (Figure 1).

***Changes in the colon histopathology***

Rat colons were observed by light microscopy (Figure 2). The HC, HC-7, and HC-14 groups had similar histopathologies, with intact colonic mucosal epithelia, regularly arranged glands and evenly distributed mesenchyme. No congestion, oedema, ulcers or other pathological abnormalities were noted. By contrast, UC rats exhibited colonic mucosa damage, with a reduced number of glands and substantial inflammatory cell infiltration in the mucosa and submucosa. These abnormalities could be alleviated by moxibustion treatment, which restored the colonic mucosa to the level of healthy rats, and decreased submucosal inflammatory cell infiltration and congestion in the UC-7 and UC-14 groups. However, in the UC-W group, mucosal and submucosal glands were disorganized, with abundant inflammatory cell infiltration. The histopathological scores for the colon tissues in the different groups are presented in Figure 3. The histopathological scores in the UC group were significantly higher than those in the HC group (*P* < 0.01). After treatment, the scores were decreased in the UC-7, UC-14, UC-W, HC-7 and HC-14 groups compared with those in the UC group (*P* < 0.01).

***Core bacteria***

Approximately 3.9 million high-quality (> 220 bp) sequence reads were obtained using the MiSeq system (Illumina, San Diego, CA, USA), which led to the identification of 1545 operational taxonomic units (OTUs), with an average read length of 451.58 bp. Overall, the relative abundance levels of 18 dominant phyla were identified in the entire model system. Among these phyla, 5 (*Firmicutes*, *Bacteroidetes*, *Proteobacteria*, *Candidatus Saccharibacteria*, and *Actinobacteria*) were present at ≥ 1% and were the dominant phyla in all groups, but relative abundance varied by treatment. A total of 186 families were detected, and 100 families were commonly present, of which *Lachnospiraceae*, *Ruminococcaceae*, *Porphyromonadaceae*, *Lactobacillaceae*, *Sphingomonadaceae*, *Veillonellaceae* and *Coriobacteriaceae* were the dominant families detected. A total of 325 OTUs were identified at the genus level, of which 10 core OTUs were present in all groups. The highest average number of OTUs identified at the genus level (134) was detected in the UC-14 rats, whereas the lowest (78) was found in HC rats. As shown in Figure 4, the UC group had the most unique genera, even after treatment with either moxibustion or mesalazine gavage.

***Community abundance variation between healthy controls and UC model rats***

There were significant differences in the microbiome between healthy controls and UC rats. Although *Firmicutes* was the predominant phylum in all samples, UC rats had increased relative abundance levels of *Proteobacteria*, *Candidatus* and *Saccharibacteria* and decreased relative abundance levels of *Firmicutes* and *Actinobacteria* compared with HC rats. At the family level, UC rats had decreased *Lactobacillaceae* and *Ruminococcaceae* and increased *Sphingomonadaceae*, *Pseudomonadaceae* and *Porphyromonadaceae* (Figure 5B). In addition, *Lactobacillus*, *Clostridium XlVa* and *Ruminococcus* were increased and *Saccharibacteria* and *Sphingomonas* were decreased in HC compared with UC rats (Figure 5C). UC rats had lower alpha diversity than HC rats, and the Shannon Diversity Index was reduced (Figure 5D), consistent with previous reports[15,40].

***Community abundance variations between healthy controls with or without moxibustion treatment***

In HC-7 and HC-14 groups, *Firmicutes* were decreased and *Bacteroidetes* and *Proteobacteria* were increasedcompared with the HC group (Figure 5A). At the family level, *Porphyromonadaceae* was increased and *Ruminococcaceae* and *Veillonellaceae* were decreased in moxibustion-treated groups (Figure 5B). Compared with the HC-7 group, the HC-14 group had increased abundance levels of *Lachnospiraceae* and *Ruminococcaceae* and a decreased abundance of *Lactobacillaceae*. At the genus level, *Lactobacillus* and *Desulfovibrio* were significantly increased, and *Ruminococcus* and *Barnesiella* were significantly decreased in both HC-7 and HC-14 groups relative to HCs. In particular, significant differences between HC-7 and HC-14 were noted regarding the abundance levels of *Lactobacillus*, *Saccharibacteria*, and *Blautia*. HC-7 exhibited increased abundance levels of *Lactobacillus* and *Blautia* and a reduced abundance of *Saccharibacteria* compared with those in the HC-14 group. *Lactobacillus* and *Pseudomonas* were significantly enriched in HC-7 (but not HC-14) compared with the HC group. Interestingly, *Saccharibacteria* was decreased in HC-7 but increased in HC-14 compared with HCs (Figure 5C). It is not clear why the alpha diversity was decreased in HC-7 but increased in HC-14 compared with HCs (Figure 5D).

***Community abundance variations between UC groups with or without moxibustion treatment***

Moxibustion treatment (but not mesalazine gavage) for 7 or 14 d was associated with an increase in *Firmicutes* compared with the UC group, whereas*Proteobacteria* *Candidatus* and *Saccharibacteria* were decreased to varying degrees in both the moxibustion- and mesalazine-treated groups compared with the UC group. *Bacteroidetes* was reduced in UC-14 but substantially increased in the UC-W group compared with the UC group. At the family level, UC-7 was similar to UC-W but significantly different from UC-14. UC-14 exhibited increased *Sphingomonadaceae* and decreased *Porphyromonadaceae* compared with UC-7 and UC-W. *Coriobacteriaceae*, *Pseudomonadaceae* and *Bifidobacteriaceae* were significantly reduced in UC-7, UC-14 and UC-W groups compared with the UC group. UC-14 had relatively low levels of *Lactobacillus* but relatively high levels of *Clostridium XIVa* and *Sphingomonas* with a dominant position in all groups. In the UC-W group, *Saccharibacteria* was decreased and *Barnesiella*, *Prevotella* and *Alloprevotella* were increased significantly compared with all of the other groups.

***Biodiversity and microbial richness***

Alpha diversity was estimated through rarefaction analysis and the Shannon and Chao1 indexes. The lowest OTU richness was observed in the HC groups. Multiple rarefaction curves analysis indicated variation among samples and exhibited sufficient data coverage for diversity in the samples. The Shannon Wiener index showed the lowest value of evenness in HC rats. Surprisingly, HC-7 also showed a lower value. Interestingly, after 7 d of treatment with moxibustion, the genus-level diversity was comparable to that of HCs but notably different from the UC-14 and UC-W groups (Figure 5C). UC-7 and UC-W had the highest median alpha diversity, which was restored to the normal level of HC and HC-14. This finding suggests that both moxibustion treatment and mesalazine gavage increased colonic microbial diversity. In terms of beta-diversity, UC samples clustered separately from HC samples in a principal coordinates analysis (PCoA), indicating that disease state was the primary factor influencing community differences (Figure 6). UC -7 was more similar to UC-W on the first axis, whereas HC-7 and HC-14 were more similar to HC and UC-14. Using non-metric multidimensional scaling (nMDS) instead of PCoA produced similar results (Figure 7).

***Genus-level differences among treatment groups***

To establish which taxa were contributing most to the apparent differences in diversity between groups, genus-level abundance was assessed. *Saccharibacteria*, *Ruminococcus*, *Sphingomonas*, *Pseudomonas*, *Clostridium IV*, *Prevotella* and *Alloprevotella* were the most affected genera (Figure 8). These opportunistic pathogens can cause infection and may be important contributing factors in UC pathogenesis. Indeed, both *Bacteroidetes*[41] and *Clostridium IV*[42]are associated with UC. In our study, we found that UC rats had a higher density of *Bacteroidetes* and reduced *Clostridium IV* compared with the control.

***Predictive functional profiling of microbial communities***

Community function was inferred from 16S compositional data using PICRUSt. In the KEGG pathway analysis, ascorbate and aldarate metabolism were significantly increased in both UC and HC rats treated with moxibustion for 14 d (Supplement Table 1), which suggests that long-term moxibustion treatment could increase ascorbate and aldarate metabolism. Furthermore, compared with the HC group, the HC-7 and HC-14 groups had significant increases in genes belonging to the amino acid metabolism pathway. Compared with the UC group, these genes were increased in the UC-7 and UC-14 groups, but no significant differences were noted. However, the roles of these metabolic pathways in UC are unclear.

***Levels of IL-6, IL-10, IL-12, IL-17, IL-23, TNF-α, TNFR1 and TNFR2 mRNA in colon mucosa***

IL-6, IL-17, IL-23, TNF-α, TNFR1 and TNFR2 (*P* < 0.01) and IL-12 mRNA (*P* < 0.05) exhibited significant increases and IL-10 mRNA (*P* < 0.01) exhibited significant decreases in the UC rats compared with their expression levels in HC rats (Figure 9). We found significantly lower levels of IL-17, IL-23, TNF-α, TNFR2 (*P* < 0.01), IL-6, IL-12, and TNFR1 mRNA (*P* < 0.05) in the UC-7 group than in the UC group. The relative expression levels of IL-6, IL-12, IL-17, IL-23 (*P* < 0.01), TNF-α and TNFR1 mRNA (*P* < 0.05) were also lower in the UC-14 group than in the UC group, and IL-10 mRNA was both higher in the UC-7 group (*P* < 0.01) and the UC-14 group (*P* < 0.01) and UC-W (*P* < 0.05) group than in the UC group. However, no significant differences in the relative expression levels of TNFR2 mRNA were noted between the UC-14 and UC groups (*P* > 0.05). Significant decreases in IL-6, IL-17, IL-23, TNF-α, TNFR1, TNFR2 mRNA (*P* < 0.01) were also noted in the UC-W group compared with the UC group.

***The levels of IL-2, IL-10, IL-12, IL-17, IL-23, IFN-γ, LPS, IgA, TGF-β, TNF-α, TNFR1 and TNFR2 in serum***

As shown in Figure 10, we noted that a lower amount of IL-2, IL-10 (*P* < 0.01) and TGF-β (*P* < 0.05) and a higher levels of IL-12 (*P* < 0.05), IL-17, IL-23, IFN-γ, LPS, IgA, TNF-α, TNFR1 and TNFR2 (*P* < 0.01) in UC group compared with HC group. Interestingly, we also noted a significantly higher of IL-2 (*P* < 0.01), IL-10 (UC-7, *P* < 0.05; UC-W and HC-7, *P* < 0.01) and TGF-β (UC-7 and UC-W, *P* < 0.05; HC-7, *P* > 0.05) in treatment groups than UC group. Similarly, the levels of IL-17 (UC-7 and HC-7, *P* < 0.05; UC-W, *P* < 0.01), IL-23, IFN-γ, LPS, IgA, TNFR1, TNFR2 (*P* < 0.01), TNF-α (*P* < 0.05) in serum were lower in UC-7 and UC-W groups. However, there were no significant differences in the level of IL-12 neither between UC group and UC-7 group nor between UC group and UC-W group (*P* > 0.05). The results were not completely consistent with the PCR. ELISA is a quantitative method to detect proteins, and PCR is the detection of the target genes from the transcription level, rather than protein, from transcription to translation there are complex processes, so the expression of genes and protein expression is not necessarily positive correlation.

**DISCUSSION**

In the last decade, several studies have revealed a strong association between gut microbiome dysbiosis and UC[17,43-45]. According to the traditional Chinese medicine theory, the Tianshu (ST25) acupoint is the Mu point of large intestine and can regulate gastrointestinal functions, is usually used to abdominal pain and diarrhea[46]. Moxibustion is an effective and safe treatment for UC, but the underlying mechanism remains unknown. Moxibustion treatment regulates intestinal flora and inhibits TNF-α and IL-12 expression in the colon tissues of UC rats, which can regulate the colonic immune response[30]. However, no study has investigated the effects of moxibustion on the intestinal flora using whole microbiome analysis. Therefore, we employed a 16S rRNA amplicon sequencing approach to determine the effects of moxibustion treatment on the microbiome in a UC rat model.

We found that moxibustion treatment increased *Firmicutes* abundance and decreased the abundance levels of *Bacteroidetes* and *Proteobacteria*. In terms of alpha diversity, HC-14 was more similar to HC than HC-7, which was confirmed by PCoA. In terms of alpha diversity, UC-14 was also more similar to UC than UC-7. This finding suggests that short-term (7 d) but no longer term (14 d) moxibustion treatment may significantly affect the gut microbiome. Overall, the relative abundance levels of beneficial bacteria were decreased, and the growth of several opportunistic pathogenic species was increased in the UC rats.

We found that gut microbiome diversity was significantly reduced in UC rats compared with healthy controls, consistent with previous reports. The abundance levels of *Firmicutes*, *Bacteroidetes* and *Proteobacteria Candidatus* varied between treatment groups. In particular, *Firmicutes* was less abundant in UC rats. At the family level, this effect translated to reductions in host beneficial taxa, including *Ruminococcaceae* and *Lactobacillaceae*, which are closely associated with UC[47]. At the genus level, *Lactobacillus*, *Bifidobacterium* and *Ruminococcus* were decreased in UC rats, consistent with the literature[15,46]. Several studies have reported that *Lactobacillus* and *Bifidobacterium* played key roles in treating UC patients or rats by inhibiting Toll-like receptor 4 expression to reduce TNF-α expression[47] and enhancing anti-inflammatory cytokine IL-10 production[48]. UC pathogenesis may be associated with the decreased levels of *Lactobacillus* and *Bifidobacterium*, which consequently led to increases in inflammatory cytokines and decreases in anti-inflammatory cytokines. *Lactobacillus* and *Bifidobacterium* can down-regulate inflammatory cytokines[49] and stimulate anti-inflammatory cytokines, such as IL-10[50], which may protect the host from mucosal inflammation. Interestingly, we found that the expression levels of inflammatory cytokines, such as IL-6, IL-12, IL-17, IL-23, IFN-γ, TNF-α, TNFR1 and TNFR2, were increased and that anti-inflammatory cytokine IL-10 and TGF-β expression was decreased in UC rats compared with HC rats. These results indicate that gut microbial variation may affect mucosal immunity through up-regulating inflammatory cytokines and down-regulating anti-inflammatory cytokines. However, the specific relationship between gut microbiome and mucosal immunity needs further investigation. After moxibustion treatment, the levels of these inflammatory cytokines were significantly decreased, and anti-inflammatory cytokines were increased. These results demonstrated that moxibustion treatment may repair intestinal mucosal by down-regulating inflammatory cytokines and up-regulating anti-inflammatory cytokines. In an animal model of colitis, butyrate-producing bacteria alleviated intestinal inflammation and necrosis in colitic rats[50]. UC patients have fewer butyrate-producing bacteria, such as *Clostridium leptum* and *Clostridium coccoides*[51,52], which is supported by our findings.

In UC rats, both moxibustion and mesalazine gavage for 7 d led to increases in microbial diversity. Several studies have reported that mesalazine can improve the clinical symptoms and colon mucosal condition in UC patients[53,54]. These results demonstrate that moxibustion could potentially be used as an alternative treatment to mesalazine. It is not clear why the alpha diversity was decreased in UC rats treated with moxibustion for 14 d. It is possible that moxibustion is not suitable for long-term treatment of UC, and determining whether moxibustion has side effects requires further study. PCoA analysis showed that UC rats had distinct microbiome profiles compared with HC rats, and an increased similarity in PCoA axis scores was noted between the HC and UC-14 groups. These results indicate that moxibustion could possibly decrease distinct bacteria, such as [opportunistic](javascript:void(0);) [pathogen](javascript:void(0);)s.

High-throughput sequencing offers a new tool for studying the effect of moxibustion on the gut microbiome and its mechanism of action. Here, we report reduced diversity, gut microbial dysbiosis, increased inflammatory cytokines and decreased anti-inflammatory cytokines in DSS-induced colitis rats and show that these effects could be alleviated by moxibustion treatment. Our findings suggest that moxibustion exerts its therapeutic effect by modulating the microbiome and intestinal mucosal immunity. Bacterial functions possibly associated with moxibustion treatment include ascorbate and aldarate metabolism and amino acid metabolism.

**ARITLCE HIGHLIGHTS**

***Research background***

The etiology and pathogenesis of ulcerative colitis (UC) are not clear, in recent years, there was growing evidence that the gut microbiota has a key role in the development of UC. Our previous study has shown that there are an imbalanced states of the beneficial bacteria *Bifidobacterium*, *Lactobacillus*, and harmful bacteria *E. coli* and *Fusobacterium* in the intestine of UC rats, and moxibustion can regulate the balance of beneficial bacteria and harmful bacteria in the intestine of UC rats.

***Research motivation***

Many studies have confirmed the efficacy of moxibustion in UC, however, the role of gut microbiota in the pathogenesis of UC and the role of moxibustion in the regulation of UC gut microbiota remain unclear.

***Research objectives***

The aim of this work is to investigate the effect and mechanism of moxibustion on gut microbiota in UC rats.

***Research methods***

UC was induced with 4% DSS in drinking water for 7 consecutive days. Moxibustion was applied to the Tianshu (ST25, bilateral). Haematoxylin and eosin staining was assessed to evaluate the changes in the colon histopathology. Gut microbiome profiling was conducted by 16S rRNA amplicon sequencing, and the expression of inflammatory cytokines was determined by PCR and ELISA.

***Research results***

Compared with the healthy controls (HC) group, the UC group had increased histopathological scores. After treatment, the scores were decreased in the UC-7, UC-14, UC-W, HC-7 and HC-14 groups compared with those in the UC group. The relative abundance of some of the bacteria in the UC group was changed at both the phylum, family and genus level, in addition, UC rats had reduced alpha diversity, which all could be alleviated by moxibustion therapy. Moxibustion can significantly reduce the levels of pro-inflammatory cytokines IL-6, IL-12, IL-17, IL-23, IFN-γ, LPS, TNF-α, TNFR1 and TNFR2 and increase anti-inflammatory cytokines IL-2 and TGF-β in rats with ulcerative colitis and reduce the intestinal inflammation.

***Research conclusions***

Our findings suggest that moxibustion exerts its therapeutic effect by modulating the microbiome and intestinal mucosal immunity.

***Research perspectives***

The present study may provide a certain experimental basis and scientific basis for the clinical curative effect of the treatment of UC.

**ACKNOWLEDGEMENTS**

We want to thank Realbio Genomics Institute for 16S rRNA sequencing and data analysis.

**REFERENCES**

1 **O'Hara AM**, Shanahan F. The gut flora as a forgotten organ. *EMBO Rep* 2006; **7**: 688-693 [PMID: 16819463 DOI: 10.1038/sj.embor.7400731]

2 **Ubeda C**, Pamer EG. Antibiotics, microbiota, and immune defense. *Trends Immunol* 2012; **33**: 459-466 [PMID: 22677185 DOI: 10.1016/j.it.2012.05.003]

3 **Khan I**, Yasir M, Azhar EI, Kumosani T, Barbour EK, Bibi F, Kamal MA. Implication of gut microbiota in human health. *CNS Neurol Disord Drug Targets* 2014; **13**: 1325-1333 [PMID: 25345506 DOI: 10.2174/1871527313666141023153506]

4 **Clemente JC**, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. *Cell* 2012; **148**: 1258-1270 [PMID: 22424233 DOI: 10.1016/j.cell.2012.01.035]

5 **Sekirov I**, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. *Physiol Rev* 2010; **90**: 859-904 [PMID: 20664075 DOI: 10.1152/physrev.00045.2009]

6 **Ayres JS**. Cooperative Microbial Tolerance Behaviors in Host-Microbiota Mutualism. *Cell* 2016; **165**: 1323-1331 [PMID: 27259146 DOI: 10.1016/j.cell.2016.05.049]

7 **Zeng MY**, Cisalpino D, Varadarajan S, Hellman J, Warren HS, Cascalho M, Inohara N, Núñez G. Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens. *Immunity* 2016; **44**: 647-658 [PMID: 26944199 DOI: 10.1016/j.immuni.2016.02.006]

8 **Hooper LV**, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science* 2012; **336**: 1268-1273 [PMID: 22674334 DOI: 10.1126/science.1223490]

9 **Dorrestein PC**, Mazmanian SK, Knight R. Finding the missing links among metabolites, microbes, and the host. *Immunity* 2014; **40**: 824-832 [PMID: 24950202 DOI: 10.1016/j.immuni.2014.05.015]

10 **Baumgart DC**, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet* 2007; **369**: 1641-1657 [PMID: 17499606 DOI: 10.1016/S0140-6736(07)60751-X]

11 **M'Koma AE**. Inflammatory bowel disease: an expanding global health problem. *Clin Med Insights Gastroenterol* 2013; **6**: 33-47 [PMID: 24833941 DOI: 10.4137/CGast.S12731]

12 **Ng SC**, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. *Aliment Pharmacol Ther* 2013; **38**: 854-863 [PMID: 23981095 DOI: 10.1111/apt.12464]

13 **Goyal N**, Rana A, Ahlawat A, Bijjem KR, Kumar P. Animal models of inflammatory bowel disease: a review. *Inflammopharmacology* 2014; **22**: 219-233 [PMID: 24906689 DOI: 10.1007/s10787-014-0207-y]

14 **Braun J**, Wei B. Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. *Annu Rev Pathol* 2007; **2**: 401-429 [PMID: 18039105 DOI: 10.1146/annurev.pathol.1.110304.100128]

15 **Michail S**, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J, Leleiko N, Kenche H, Stolfi A, Wine E. Alterations in the gut microbiome of children with severe ulcerative colitis. *Inflamm Bowel Dis* 2012; **18**: 1799-1808 [PMID: 22170749 DOI: 10.1002/ibd.22860]

16 **Manichanh C**, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 599-608 [PMID: 22907164 DOI: 10.1038/nrgastro.2012.152]

17 **Rajilić-Stojanović M**, Shanahan F, Guarner F, de Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. *Inflamm Bowel Dis* 2013; **19**: 481-488 [PMID: 23385241 DOI: 10.1097/MIB.0b013e31827fec6d]

18 **Kump PK**, Gröchenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ, Gorkiewicz G, Högenauer C. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. *Inflamm Bowel Dis* 2013; **19**: 2155-2165 [PMID: 23899544 DOI: 10.1097/MIB.0b013e31829ea325]

19 **Machiels K**, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. *Gut* 2014; **63**: 1275-1283 [PMID: 24021287 DOI: 10.1136/gutjnl-2013-304833]

20 **Ji J**, Lu Y, Liu H, Feng H, Zhang F, Wu L, Cui Y, Wu H. Acupuncture and moxibustion for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. *Evid Based Complement Alternat Med* 2013; **2013**: 158352 [PMID: 24204388 DOI: 10.1155/2013/158352]

21 **Wu HG**, Zhou LB, Shi DR, Liu SM, Liu HR, Zhang BM, Chen HP, Zhang LS. Morphological study on colonic pathology in ulcerative colitis treated by moxibustion. *World J Gastroenterol* 2000; **6**: 861-865 [PMID: 11819709 DOI: 10.3748/wjg.v6.i6.861]

22 **Joos S**, Wildau N, Kohnen R, Szecsenyi J, Schuppan D, Willich SN, Hahn EG, Brinkhaus B. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. *Scand J Gastroenterol* 2006; **41**: 1056-1063 [PMID: 16938719 DOI: 10.1080/00365520600580688]

23 **Mu JP**, Wu HG, Zhang ZQ, Liu HR, Zhu Y, Shi Z, Wang XM. [Meta-analysis on acupuncture and moxibustion for treatment of ulcerative colitis]. *Zhongguo Zhen Jiu* 2007; **27**: 687-690 [PMID: 17926625]

24 **Han Y**, Ma TM, Lu ML, Ren L, Ma XD, Bai ZH. Role of moxibustion in inflammatory responses during treatment of rat ulcerative colitis. *World J Gastroenterol* 2014; **20**: 11297-11304 [PMID: 25170214 DOI: 10.3748/wjg.v20.i32.11297]

25 **Wang X**, Liu Y, Dong H, Wu L, Feng X, Zhou Z, Zhao C, Liu H, Wu H. Herb-Partitioned Moxibustion Regulates the TLR2/NF-κB Signaling Pathway in a Rat Model of Ulcerative Colitis. *Evid Based Complement Alternat Med* 2015; **2015**: 949065 [PMID: 26339273 DOI: 10.1155/2015/949065]

26 **Wu HG**, Huang Z, Liu HR, Zhang W, Shi Y, Zhu Y, Cui YH, Liu SM. [Experimental study on influence of acupuncture and moxibustion therapy on apoptosis of colonic epithelial cells in rats of ulcerative colitis]. *Zhongguo Zhen Jiu* 2005; **25**: 119-122 [PMID: 16312896]

27 **Wu HG**, Liu HR, Tan LY, Gong YJ, Shi Y, Zhao TP, Yi Y, Yang Y. Electroacupuncture and moxibustion promote neutrophil apoptosis and improve ulcerative colitis in rats. *Dig Dis Sci* 2007; **52**: 379-384 [PMID: 17211698 DOI: 10.1007/s10620-006-9561-y]

28 **Huang Y,** Zhao JM, Guan X, Zhang JB, Dou CZ, Shi Z, Liu HR, Wang XM, Wu HG. Effect of Warming Moxibustion on P2RX7 Regulation in Tianshu Acupoint Skin of Rats with Ulcerative Colitis. *Shijie Kexuejishu – Zhongyiyao Xiandaihua* 2016; **18**: 389-394

29 **Zhou EH**, Liu HR, Wu HG, Shi Z, Zhang W, Zhu Y, Shi DR, Zhou S. Down-regulation of protein and mRNA expression of IL-8 and ICAM-1 in colon tissue of ulcerative colitis patients by partition-herb moxibustion. *Dig Dis Sci* 2009; **54**: 2198-2206 [PMID: 19083096 DOI: 10.1007/s10620-008-0620-4]

30 **Wang XM**, Lu Y, Wu LY, Yu SG, Zhao BX, Hu HY, Wu HG, Bao CH, Liu HR, Wang JH, Yao Y, Hua XG, Guo HY, Shen LR. Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis. *World J Gastroenterol* 2012; **18**: 6819-6828 [PMID: 23239920 DOI: 10.3748/wjg.v18.i46.6819]

31 **Kostic AD**, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology* 2014; **146**: 1489-1499 [PMID: 24560869 DOI: 10.1053/j.gastro.2014.02.009]

32 **The Ministry of Science and Technology of the People’s Republic of China.** Guidance Suggestions for the Care and Use of Laboratory Animals. 2006. Available from: URL: http://www.most.gov.cn/fggw/zfwj/zfwj2006/200609/t20060930\_54389.htm

33 **Fichna J**, Dicay M, Lewellyn K, Janecka A, Zjawiony JK, MacNaughton WK, Storr MA. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. *Inflamm Bowel Dis* 2012; **18**: 1137-1145 [PMID: 21953882 DOI: 10.1002/ibd.21873]

34 **Weng ZJ**, Wu LY, Zhou CL, Dou CZ, Shi Y, Liu HR, Wu HG. Effect of electroacupuncture on P2X3 receptor regulation in the peripheral and central nervous systems of rats with visceral pain caused by irritable bowel syndrome. *Purinergic Signal* 2015; **11**: 321-329 [PMID: 25809868 DOI: 10.1007/s11302-015-9447-6]

35 **Hamady M**, Walker JJ, Harris JK, Gold NJ, Knight R. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. *Nat Methods* 2008; **5**: 235-237 [PMID: 18264105 DOI: 10.1038/nmeth.1184]

36 **Cole JR**, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ, Kulam-Syed-Mohideen AS, McGarrell DM, Marsh T, Garrity GM, Tiedje JM. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. *Nucleic Acids Res* 2009; **37**: D141-D145 [PMID: 19004872 DOI: 10.1093/nar/gkn879]

37 **Langille MG**, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013; **31**: 814-821 [PMID: 23975157 DOI: 10.1038/nbt.2676]

38 **Parks DH**, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. *Bioinformatics* 2014; **30**: 3123-3124 [PMID: 25061070 DOI: 10.1093/bioinformatics/btu494]

39 **Parks DH**, Beiko RG. Identifying biologically relevant differences between metagenomic communities. *Bioinformatics* 2010; **26**: 715-721 [PMID: 20130030 DOI: 10.1093/bioinformatics/btq041]

40 **Lepage P**, Häsler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, Ott S, Kupcinskas L, Doré J, Raedler A, Schreiber S. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. *Gastroenterology* 2011; **141**: 227-236 [PMID: 21621540 DOI: 10.1053/j.gastro.2011.04.011]

41 **Lucke K**, Miehlke S, Jacobs E, Schuppler M. Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. *J Med Microbiol* 2006; **55**: 617-624 [PMID: 16585651 DOI: 10.1099/jmm.0.46198-0]

42 **Matsuoka K**, Kanai T. The gut microbiota and inflammatory bowel disease. *Semin Immunopathol* 2015; **37**: 47-55 [PMID: 25420450 DOI: 10.1007/s00281-014-0454-4]

43 **Sartor RB**. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008; **134**: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]

44 **Trier JS**. Mucosal flora in inflammatory bowel disease: Intraepithelial bacteria or endocrine epithelial cell secretory granules? *Gastroenterology* 2002; **123**: 955; author reply 956 [PMID: 12198731 DOI: 10.1016/S0016-5085(02)70059-0]

45 **Hanning IB,** Lingbeck JM, Ricke SC. Probiotics and Heart Health: Reduction of Risk Factors Associated with Cardiovascular Disease and Complications Due to Foodborne Illnesses. In: Watson RR, Preedy VR, editors. Bioactive Foods in Promoting Health: Probiotics and Prebiotics. Amsterdam: Elsevier Inc, 2010: 423-439 [DOI: 10.1016/B978-0-12-374938-3.00026-8]

46 **Zhang D**, Ren YB, Wu HG, Yang YT, Wu LJ, Zhang J, Shi Z, Ma XP. [Effect of Different Doses of Herbal Cake-partitioned Moxibustion on Histopathological Changes of Colon Tissue in Ulcerative Colitis Rats]. *Zhen Ci Yan Jiu* 2018; **43**: 68-74 [PMID: 29516692 DOI: 10.13702/j.1000-0607.170843]

47 **Yang X**, Fu Y, Liu J, Ren HY. Impact of probiotics on toll-like receptor 4 expression in an experimental model of ulcerative colitis. *J Huazhong Univ Sci Technolog Med Sci* 2013; **33**: 661-665 [PMID: 24142717 DOI: 10.1007/s11596-013-1177-9]

48 **Imaoka A**, Shima T, Kato K, Mizuno S, Uehara T, Matsumoto S, Setoyama H, Hara T, Umesaki Y. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. *World J Gastroenterol* 2008; **14**: 2511-2516 [PMID: 18442197 DOI: 10.3748/wjg.14.2511]

49 **Llopis M**, Antolin M, Carol M, Borruel N, Casellas F, Martinez C, Espín-Basany E, Guarner F, Malagelada JR. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. *Inflamm Bowel Dis* 2009; **15**: 275-283 [PMID: 18839424 DOI: 10.1002/ibd.20736]

50 **Sokol H**, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 2008; **105**: 16731-16736 [PMID: 18936492 DOI: 10.1073/pnas.0804812105]

51 **Andoh A**, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikawa T, Fujiyama Y. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. *J Gastroenterol* 2011; **46**: 479-486 [PMID: 21253779 DOI: 10.1007/s00535-010-0368-4]

52 **Manichanh C**, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* 2006; **55**: 205-211 [PMID: 16188921 DOI: 10.1136/gut.2005.073817]

53 **Liu B**, Piao X, Guo L, Wang G, Sun W, Gao L, Zheng X, Fang Y. A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis. *Evid Based Complement Alternat Med* 2017; **2017**: 7323129 [PMID: 29358969 DOI: 10.1155/2017/7323129]

54 **Solberg IC**, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). *Scand J Gastroenterol* 2009; **44**: 431-440 [PMID: 19101844 DOI: 10.1080/00365520802600961]

**P-Reviewer:** Raghow R, Suzuki H Watanabe T **S-Editor:** Wang JL

**L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0




**Figure 1 Body weight gains after treatment in different groups.** HC: healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: healthy controls with 7 d of moxibustion; HC-14: healthy controls with 14 d of moxibustion. The body weight gain in the UC group was decreased compared with the HC group (*P* < 0.01). After treatment, the body weight gains in the UC-7, UC-14, HC-7, HC-14 (*P* < 0.01) and UC-W (*P* < 0.05) groups were increased compared with the UC group. *bP* < 0.01, *vs* the HC group;*cP* < 0.05, *dP* < 0.01, *vs* the UC group.




**Figure 2 Rat colon tissue pathology under different treatments.** HC: healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with 7 d of moxibustion; HC-14: Healthy controls with 14 d of moxibustion. The colonic mucosa in HC, HC-7, and HC-14 rats exhibited no pathological abnormalities. The colonic mucosa was damaged in the UC group, with a reduction in the number of glands and cell infiltration. After moxibustion treatment, decreased cell infiltration and congestion were noted in the UC-7 and UC-14 groups. Glands were disorganized with abundant inflammatory cell infiltration in the UC-W group. Red arrow indicated inflammatory cell infiltration and green arrow indicate gland (magnification: 200×).

****


**Figure 3 Histopathological scores for colon tissue in the different groups.** HC: healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with 7 d of moxibustion; HC-14: Healthy controls with 14 d of moxibustion. The histopathological scores in the UC group were significantly increased compared with the HC group (*P* < 0.01). After treatment, the scores were decreased in the UC-7, UC-14, UC-W, HC-7 and HC-14 groups compared with the UC group (*P* < 0.01). *bP* < 0.01, *vs* the HC group;*dP* < 0.01, *vs* the UC group.


****

**Figure 4 Summary of operational taxonomic units identified at the genus level in each group.** HC: healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with 7 d of moxibustion; HC-14: Healthy controls with 14 d of moxibustion. There were 10 core operational taxonomic units in all groups. The UC group had the most unique genera.


****


**Figure 5 Comparative analysis of the dominant phyla, families and genera under different treatments.** HC: healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with 7 d of moxibustion; HC-14: Healthy controls with 14 d of moxibustion. A:The relative abundance levels of *Proteobacteria*, *Candidatus* and *Saccharibacteria* were increased, whereas *Firmicutes* and *Actinobacteria* were decreased in the UC group compared with the HC group. These changes in microbiota profiles could be reversed by moxibustion treatment for 7 or 14 d;B: UC rats had decreased *Lactobacillaceae* and *Ruminococcaceae* and increased *Sphingomonadaceae*, *Pseudomonadaceae* and *Porphyromonadaceae* compared with the HC group. After treatment, *Pseudomonadaceae* was reduced in the UC-7, UC-14 and UC-W groups compared with the UC group; C: *Lactobacillus*, *Clostridium* XlVa and *Ruminococcus* were increased and *Saccharibacteria* and *Sphingomonas* were decreased in HC rats compared with UC rats; D: UC rats had decreased alpha diversity compared with HC rats. After treatment, alpha diversity was increased in the UC-7 and UC-W groups.

**Figure 6 Beta diversity analysis by PCoA.** HC: Healthy controls; UC: UC Model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with 7 d of moxibustion; HC-14: Healthy controls with 14 d of moxibustion. UC samples clustered separately from HC samples. The UC-7 group was more similar to the UC-W group on the first axis, whereas the HC-7 and HC-14 groups were more similar to the HC and UC-14 groups. Sample colour is based on treatment group.


****

**Figure 7 Non-metric multidimensional scaling between groups.**

**Figure 8 Genus-level differences between treatment groups.** HC: Healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with 7 d of moxibustion; HC-14: Healthy controls with 14 d of moxibustion. UC rats had a higher density of Bacteroidetes and a lower Clostridium IV density compared with HC rats.

****

**Figure 9 The relative expression levels of IL-6, IL-10, IL-12, IL-17, IL-23, TNF-α, TNFR1 and TNFR2 in colon mucosa.** HC: healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-14: UC model with 14 d of moxibustion; UC-W: UC model with mesalazine gavage. The relative expression levels of IL-12 (*P* < 0.05), IL-6, IL-17, IL-23, TNF-α, TNFR1 and TNFR2 (*P* < 0.01) in the UC group were increased compared with the HC group. IL-10 (*P* < 0.01) expression levels in the UC group were decreased compared with the HC group. IL-17, IL-23, TNF-α, TNFR2 (*P* < 0.01), IL-6, IL-12, and TNFR1 (*P* < 0.05) expression levels were decreased in the UC-7 group compared with the UC group. TNF-α and TNFR1 (*P* < 0.05), IL-12, IL-6, IL-17, IL-23 (*P* < 0.01) expression levels in the UC-14 group were decreased compared with UC rats. IL-10 was both higher in the UC-7 group (*P* < 0.01) and the UC-14 group (*P* < 0.01) and the UC-W group (*P* < 0.05) than in the UC group. IL-6, IL-17, IL-23, TNF-α, TNFR1, TNFR2 (*P* < 0.01) expression levels were decreased in the UC-W group compared with the UC group.a*P* < 0.05,b*P* < 0.01, *vs* the HC group; c*P* < 0.05, d*P* < 0.01, *vs* the UC group.

****

**Figure 10 The levels of IL-2, IL-10, IL-12, IL-17, IL-23, IFN-γ, LPS, IgA, TGF-β, TNF-α, TNFR1 and TNFR2 in serum.** HC: Healthy controls; UC: UC model group; UC-7: UC model with 7 d of moxibustion; UC-W: UC model with mesalazine gavage; HC-7: Healthy controls with 7 d of moxibustion. IL-2, IL-10 (*P* < 0.01) and TGF-β (*P* < 0.05) were lower and IL-12 (*P* < 0.05), IL-17, IL-23, IFN-γ, LPS, IgA, TNF-α, TNFR1 and TNFR2 (*P* < 0.01) were higher in UC group compared with HC group. The levels of IL-2 (*P* < 0.01), IL-10 (UC-7, *P* < 0.05; UC-W and HC-7, *P* < 0.01) and TGF-β (UC-7 and UC-W, *P* < 0.05; HC-7, *P* > 0.05) were higher in treatment groups than UC group. The levels of IL-17 (UC-7 and HC-7, *P* < 0.05; UC-W, *P* < 0.01), IL-23, IFN-γ, LPS, IgA, TNFR1, TNFR2 (*P* < 0.01), TNF-α (*P* < 0.05) in serum were lower in UC-7 and UC-W groups. However, there were no significant differences in the level of IL-12 neither between UC group and UC-7 group nor between UC group and UC-W group (*P* > 0.05). *aP* < 0.05, *bP* < 0.01, *vs* the HC group; *cP* < 0.05, *dP* < 0.01, *vs* the UC group.

**Table 1 Histopathological scores**

|  |  |  |
| --- | --- | --- |
| **Histopathological manifestation** | | **score** |
| Ulcer | no ulcer | 0 |
|  | ulcer area < 3 cm | 1 |
|  | ulcer area > 3 cm | 2 |
| Inflammation | no inflammation | 0 |
|  | mild inflammation | 1 |
|  | severe inflammation | 2 |
| Granuloma  Lesion depth  Fibrosis | no granuloma  granuloma  no lesion  submucosa  muscular layer  serosa layer  no fibrosis  mild fibrosis  severe fibrosis | 0  1  0  1  2  3  0  1  2 |

**Table 2 Primer sequences**

|  |  |  |  |
| --- | --- | --- | --- |
| **Target Gene** | | **Forward sequence** | **Reverse sequence** |
| *IL-6*  *IL-10*  *IL-12*  *IL-17*  *IL-23*  *TNF-α*  *TNFR1*  *TNFR2*  *rACTIN* | GCCAGAGTCATTCAGAGCAA  CTGTCATCGATTTCTCCCCT  CCCTCAAGTTCTTCGTCCGC  ATCCAGCAAGAGATCCTGGT  TGTGGTGATGGTTGTGATCC  GAAAGCATGATCCGAGATGT  TGAGACGCATTTCCAGTGTG  CATGTCAACGTCACCTGCAT  ACTTCGAGCAGGAGATGGCC | | TTGGTCCTTAGCCACTCCTT  CAAACTCATTCATGGCCTTG  TTTGCATTGGACTTCGGCAG  CAATAGAGGAAACGCAGGTG  TGTGAAGATGTCCGAGTCCA  CAGGAATGAGAAGAGGCTGA AGAATCCTGCGTGGCAGTTA  TCATCCTTTGGAGACCCTGA  CCCAGGAAGGAAGGCTGGAA |